HEPAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:34):

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States...

Stats
本日の出来高	15 028.00
平均出来高	77 775.00
時価総額	7.61M
EPS	$0 ( 2024-04-01 )
次の収益日	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.110
ATR14	$0.0200 (1.44%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Purcell Michael J.	Buy	50 000	Restricted Stock Units
2024-03-05	Purcell Michael J.	Buy	0
2024-02-19	Block Timothy M.	Buy	85 000	Stock Options
2024-02-19	Jacob Gary S	Buy	85 000	Stock Options
2024-02-19	Lbiati Kaouthar	Buy	85 000	Stock Options

INSIDER POWER
93.35
Last 96 transactions
Buy: 8 825 675 \| Sell: 984 166

ボリューム相関

長: 0.06 (neutral)

短: 0.31 (neutral)

Signal:(51.479) Neutral

Hepion Pharmaceuticals 相関

10 最も正の相関
ATCX	0.925
SYKE	0.923
RDUS	0.907
ICON	0.898
BRACU	0.898
SPRB	0.89
JFIN	0.89
BGXX	0.885
MESA	0.88
CYN	0.872

10 最も負の相関
VERA	-0.896
ARDS	-0.879
LGHL	-0.848
AHPI	-0.843
TUEM	-0.838
HRMY	-0.835
SBBP	-0.834
VIEW	-0.833
GRPH	-0.821
LCAP	-0.817

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Hepion Pharmaceuticals 相関 - 通貨/商品

0.45
( neutral )

0.59
( weak )

0.00
( neutral )

0.39
( neutral )

0.01
( neutral )

0.36
( neutral )

Hepion Pharmaceuticals 財務諸表

Annual	2023
収益:	$0
総利益:	$-67 131.00 (0.00 %)
EPS:	$-12.32

FY	2023
収益:	$0
総利益:	$-67 131.00 (0.00 %)
EPS:	$-12.32

FY	2022
収益:	$0
総利益:	$-77 461.00 (0.00 %)
EPS:	$-11.07

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.38

Financial Reports:

No articles found.

Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.